TTR and hemophilia A: Results of a second long-term study in hemophilia A dogs treated with AAV-cFVIII delivered in AAV2, AAV6, and AAV8 with the liver-specific transthyretin (TTR) promoter were presented at the roundtable, and in this case also, no transformation was detected in dog liver.